Use of Lipogems for Knee Osteoarthritis
Primary Purpose
Knee Osteoarthritis
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
autologous microfragmented lipoaspirate tissue (Lipogems®).
arthroscopic debridment
Sponsored by

About this trial
This is an interventional treatment trial for Knee Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- patients with knee osteoarthritis grade III e IV Kellgren-Lawrence,
- age between 45 and 75,
- pain ≥ 6 VAS scale,
- no ligamentous instability,axial deviation less than 10°
- BMI between 18 and 30,
- International Normalized Ratio (INR) < 1.5
Exclusion Criteria:
- previous traumatic lesion (tibial fracture, osteothomy) of the knee
- osteonecrosis
- meniscal surgery in the previous 6 weeks
- chemiotherapy, radioteherapy
- diabetes
- alchoolism, psichiatric disease,drug addiction
- coagulation disorders
- pregnancy
Sites / Locations
- Istituto Ortopedico Galeazzi
- IRCCS Istituto Ortopedico Galeazzi
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Controls
Cases
Arm Description
39 patients with knee osteoarthritis undergoing arthroscopic debridement
39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Outcomes
Primary Outcome Measures
Symptomatic and functional evaluation at 6 months by comparison of the KOOS score recorded between the two groups
Symptomatic and functional evaluation at 6 months by comparison of the KOOS score recorded between two groups (6±1 months) undergoing arthroscopic debridement ± injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Secondary Outcome Measures
Radiological changes at 6 month recorded between the two groups
Evaluation of possible radiological changes pre-operative and after 6±1 months by means of MagneticResonanceImaging analysis.
Functional changes at 6 month recorded between the two groups
Symptomatic and functional evaluation at 6±1 months by means of Proms that inclued questionnaire about quality of life (SF-12, WOMAC)
Serum changes at 6 month recorded between the two groups
Changes in serum levels of biomarkers related to Osteoarthritis (collagen type II C-telopeptide(CTx-II),collagen type III N-propeptide( PIIINP)) will be evaluated (pre-intervention vs 6±1 months).
Full Information
NCT ID
NCT04427657
First Posted
April 22, 2020
Last Updated
July 2, 2021
Sponsor
Istituto Ortopedico Galeazzi
1. Study Identification
Unique Protocol Identification Number
NCT04427657
Brief Title
Use of Lipogems for Knee Osteoarthritis
Official Title
Adipose Microfragmented Autologous Tissue for the Treatment of Knee Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
November 8, 2018 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Ortopedico Galeazzi
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Lipogems system consist in the use of a monouse kit for liposuction, processing and administration of adipose tissue. The use of the final product (microfragmented adipose tissue,not expanded) shoud promote the natural joint homeostasis, associated with a clinical improvement
Detailed Description
The Objectiveof the study is to analyse the therapeutic role of microfragmented autologous tissue for the treatment of the knee osteoarthritis (OA).
Main purpose: Symptomatic and functional evaluation at 6 months by comparison of the Knee Injury and Osteoarthritis Outcome Score(KOOS) recorded between two groups (6±1 months) undergoing arthroscopic debridement ± injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Secondary Purposes: Evaluation of possible radiological changes pre-operative and after 6±1 months by means of MagneticResonanceImage analysis. Symptomatic and functional evaluation at 6±1 months by means of VisualAnalogueScale, KneeSocietyScore, Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC). Reduction of anti-inflammatory drugs (pre-intervention versus 6±1 months). Evaluation "quality-adjusted life years" (QUALY) in relation to the questionnaire SatisfactioForm-12 (pre-intervention vs 6±1 months). Check for any adverse effects directly related to the use of micro-fragmented adipose tissue. Changes in serum levels of biomarkers related to OA (CollagenType II C-Telopeptide (CTX-II), collagen type III N-propeptide (PIIINP)) will be evaluated (pre-intervention vs 6±1 months).
The study is an interventional, prospective, randomized, controlled trial. Controls: n = 39 patients with knee osteoarthritis undergoing arthroscopic debridement. Cases: n = 39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Surgical technique: patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
78 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Controls
Arm Type
Active Comparator
Arm Description
39 patients with knee osteoarthritis undergoing arthroscopic debridement
Arm Title
Cases
Arm Type
Experimental
Arm Description
39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Intervention Type
Procedure
Intervention Name(s)
autologous microfragmented lipoaspirate tissue (Lipogems®).
Intervention Description
patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
Intervention Type
Procedure
Intervention Name(s)
arthroscopic debridment
Intervention Description
patient in supine position. Under sedation is perform an arthroscopic debridement
Primary Outcome Measure Information:
Title
Symptomatic and functional evaluation at 6 months by comparison of the KOOS score recorded between the two groups
Description
Symptomatic and functional evaluation at 6 months by comparison of the KOOS score recorded between two groups (6±1 months) undergoing arthroscopic debridement ± injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
Time Frame
6 month
Secondary Outcome Measure Information:
Title
Radiological changes at 6 month recorded between the two groups
Description
Evaluation of possible radiological changes pre-operative and after 6±1 months by means of MagneticResonanceImaging analysis.
Time Frame
6 month
Title
Functional changes at 6 month recorded between the two groups
Description
Symptomatic and functional evaluation at 6±1 months by means of Proms that inclued questionnaire about quality of life (SF-12, WOMAC)
Time Frame
6 month
Title
Serum changes at 6 month recorded between the two groups
Description
Changes in serum levels of biomarkers related to Osteoarthritis (collagen type II C-telopeptide(CTx-II),collagen type III N-propeptide( PIIINP)) will be evaluated (pre-intervention vs 6±1 months).
Time Frame
6 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
patients with knee osteoarthritis grade III e IV Kellgren-Lawrence,
age between 45 and 75,
pain ≥ 6 VAS scale,
no ligamentous instability,axial deviation less than 10°
BMI between 18 and 30,
International Normalized Ratio (INR) < 1.5
Exclusion Criteria:
previous traumatic lesion (tibial fracture, osteothomy) of the knee
osteonecrosis
meniscal surgery in the previous 6 weeks
chemiotherapy, radioteherapy
diabetes
alchoolism, psichiatric disease,drug addiction
coagulation disorders
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
michele ulivi
Organizational Affiliation
IRCCS Istituto Ortopedico GaleazziMilano
Official's Role
Principal Investigator
Facility Information:
Facility Name
Istituto Ortopedico Galeazzi
City
Milano
ZIP/Postal Code
20161
Country
Italy
Facility Name
IRCCS Istituto Ortopedico Galeazzi
City
Milan
ZIP/Postal Code
20161
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Use of Lipogems for Knee Osteoarthritis
We'll reach out to this number within 24 hrs